Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

Rhea-AI Summary

Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has scheduled its first half 2025 financial results announcement. The company will release its financial results for the period ending June 30, 2025 after U.S. markets close on August 13, 2025.

A conference call and webcast to discuss the results and business highlights will be held on August 14, 2025, at 8:00 am EDT. The presentation will be accessible through Alvotech's investor portal, with a replay available for 90 days following the event.

News Market Reaction

-1.86%

1 alert

-1.86% News Effect

On the day this news was published, ALVO declined 1.86%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

REYKJAVIK, ICELAND (August 6, 2025) – Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first half of the year ended June 30, 2025, after U.S. markets close on Wednesday, August 13, 2025.  Alvotech will also conduct a conference call to present the financial results and recent business highlights on Thursday August 14, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET).  Live audio of the conference call will be webcast and available on Alvotech’s investor portal.

Information on how to access the webcast or participate by conference call is posted on Alvotech’s investor portal https://investors.alvotech.com. Specifically, links to access the webcast and instructions to sign in by phone can be found at https://investors.alvotech.com/events/event-details/q2-2025-earnings. The webcast will also be archived and available for replay for 90 days after the event.

About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com

Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.

FAQ

When will Alvotech (NASDAQ: ALVO) release its H1 2025 financial results?

Alvotech will release its H1 2025 financial results after U.S. markets close on August 13, 2025.

What time is Alvotech's H1 2025 earnings conference call?

Alvotech's earnings conference call is scheduled for August 14, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET).

How can investors access Alvotech's H1 2025 earnings call?

Investors can access the webcast through Alvotech's investor portal at investors.alvotech.com. The webcast will be archived for replay for 90 days after the event.

What period will Alvotech's financial results cover?

The financial results will cover the first half of 2025, for the period ended June 30, 2025.